- Home
- LUCY vs VNRX Comparison
LUCY vs VNRX Comparison
Compare LUCY & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCY | VNRX |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 6.5M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | LUCY | VNRX |
|---|---|---|
| Price | $0.95 | $0.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.67 |
| AVG Volume (30 Days) | 510.2K | ★ 9.3M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.39 | 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,661,669.00 | $1,727,384.00 |
| Revenue This Year | $175.92 | $355.66 |
| Revenue Next Year | $205.56 | $849.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 62.65 | 40.04 |
| 52 Week Low | $0.65 | $0.13 |
| 52 Week High | $2.08 | $3.26 |
Technical Indicators
Market Signals| Indicator | LUCY | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.04 | 27.66 |
| Support Level | $0.90 | $0.23 |
| Resistance Level | $0.97 | $0.27 |
| Average True Range (ATR) | 0.05 | 0.02 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 85.29 | 20.03 |
Price Performance
Historical ComparisonAbout LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok. The firm derive substantially all of its revenue from the sale of smart glasses and custom lenses.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.